- Home
- PRG vs PCRX Comparison
PRG vs PCRX Comparison
Compare PRG & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRG
- PCRX
- Stock Information
- Founded
- PRG 2020
- PCRX 2006
- Country
- PRG United States
- PCRX United States
- Employees
- PRG N/A
- PCRX N/A
- Industry
- PRG Diversified Commercial Services
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- PRG Consumer Discretionary
- PCRX Health Care
- Exchange
- PRG Nasdaq
- PCRX Nasdaq
- Market Cap
- PRG 1.4B
- PCRX 1.2B
- IPO Year
- PRG N/A
- PCRX 2011
- Fundamental
- Price
- PRG $35.53
- PCRX $26.86
- Analyst Decision
- PRG Hold
- PCRX Buy
- Analyst Count
- PRG 5
- PCRX 6
- Target Price
- PRG $37.20
- PCRX $30.00
- AVG Volume (30 Days)
- PRG 302.1K
- PCRX 592.7K
- Earning Date
- PRG 10-22-2025
- PCRX 11-05-2025
- Dividend Yield
- PRG 1.46%
- PCRX N/A
- EPS Growth
- PRG 109.72
- PCRX N/A
- EPS
- PRG 5.11
- PCRX N/A
- Revenue
- PRG $2,518,216,000.00
- PCRX $705,848,000.00
- Revenue This Year
- PRG $1.44
- PCRX $7.36
- Revenue Next Year
- PRG $3.56
- PCRX $10.07
- P/E Ratio
- PRG $6.96
- PCRX N/A
- Revenue Growth
- PRG 5.17
- PCRX 2.25
- 52 Week Low
- PRG $23.50
- PCRX $13.04
- 52 Week High
- PRG $50.28
- PCRX $27.64
- Technical
- Relative Strength Index (RSI)
- PRG 60.92
- PCRX 61.04
- Support Level
- PRG $34.45
- PCRX $25.63
- Resistance Level
- PRG $36.43
- PCRX $27.11
- Average True Range (ATR)
- PRG 0.78
- PCRX 0.96
- MACD
- PRG -0.07
- PCRX -0.05
- Stochastic Oscillator
- PRG 56.94
- PCRX 68.80
About PRG PROG Holdings Inc.
PROG Holdings Inc is a financial technology holding company that provides transparent and competitive payment options to consumers. The company has two reportable segments: Progressive Leasing, an in-store, app-based, and e-commerce point-of-sale lease-to-own solutions provider; and Vive Financial (Vive), an omnichannel provider of second-look revolving credit products. The majority of the revenue of the company is earned through the Progressive Leasing segment.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.